RSS Alerts

Latest News

  • Proceedings of the 2nd Annual London Genetics Pharmacogenetics conference 2010 Pharmacogenetics: Why, How and When?
    The importance of pharmacogenetics and stratified medicine as part of the drug development processes is now widely acknowledge, offering the opportunity to address many of the challenges facing the biopharmaceutical industry today and supporting an era where cost-effectiveness and value-based pricing rule. Moving on from the inaugural London Genetics Pharmacogenetic conference in 2009, at which the role of pharmacogenetics in drug discovery and development was debated, the 2nd London Genetics conference, entitled ‘Pharmacogenetics – Why, How and When?’ focused on how and when to apply stratified approaches from drug discovery through to cost-effectiveness evaluation and reimbursement.
  • Oxford scanner reveals secrets of documents, ancient and modern
    A scanner which combines the convenience of a desktop scanner with the functionality of a powerful laboratory imaging device has been developed at the University of Oxford’s Classics Department, and is now being commercialised by a new company Oxford Multi Spectral Limited which was today spun out by the University’s technology transfer company Isis Innovation.
  • New cancer treatment device goes into service
    A treatment system called the Novalis® Tx™ has gone into service, which has the ability to destroy cancerous cells virtually anywhere in the body in a single, 20-minute session, without the need for a single cut of the scalpel.
  • Horizon successfully completes pilot human gene-editing program with leading pharma
    Horizon Discovery (Horizon), a leading provider of research tools to support the development of personalized medicines, has announced that it has successfully completed an eighteen month pilot program with Novartis, designed to test the ability of Horizon’s GENESISTM rAAV gene-editing platform to generate human isogenic cell lines for use by Novartis pre-clinical research programs.
  • Edinburgh start-up creates world’s first fluorescent protein 3D hologram to further biomedical research
    A University of Edinburgh based start-up company has created the world’s first 3D hologram based on the properties of a Nobel Prize winning scientific discovery, which enhances biomedical research into the behavioural activity of proteins.
view more

Podcasts

  • Evotec strengthens and expands its Alliance Business
    Dr Mark Ashton is Executive Vice President, Business Development of Evotec and is responsible for Evotec's commercial and partnering activities. Prior to assuming responsibility for Business Development in 2005, Dr Ashton held a number of positions within Operations at Evotec: He joined the Company in 1995 as one of the initial employees of the Discovery Division, becoming Department Manager in 2001, Director of Chemistry Services in 2002 and taking over responsibility for Evotec's Discovery Services Division in 2004, where he had responsibility for Evotec's screening, parallel synthesis and medicinal chemistry operations. During his time at Evotec, Dr Ashton has managed a wide range of pharmaceutical and biotechnology related projects, including medicinal chemistry projects, design and synthesis of screening libraries and technology transfer projects and has been involved in the progression of a number of drug candidates into the clinic in numerous therapeutic areas. Dr Ashton has authored and co-authored a number of peer reviewed papers, articles and book chapters in addition to being named on a number of pharmaceutical patents. He is trained as a medicinal chemist. Prior to joining Evotec, Dr Ashton also had spells at ICI Pharmaceuticals and Organon Laboratories. Mark Whittaker is Senior Vice President Drug Discovery at Evotec where he manages a large drug discovery collaboration and the groups of computational chemistry and structural biology. Before joining Evotec in 2001, Mark spent 13 years at British Biotech Pharmaceuticals where he led a number of medicinal chemistry programmes and was latterly Director of Chemistry. At British Biotech, Mark contributed to the discovery and development of six compounds that have progressed into human clinical trials. Before his career at British Biotech, Mark carried out post-doctoral research at the University of Oxford and at York University, Toronto and obtained a D. Phil in Chemistry from the University of York.
  • The Ubiquitin Story
    In this podcast interview with Drug Discovery Today, Nobel Prize winner Professor Aaron Ciechanover will talk about his career, his Nobel Prize-winning discovery of the UPS, and the extraordinary opportunities and challenges for drug discovery in this area.
  • Califf, Behrman and Kramer discuss the Clinical Trials Transformation Initiative.
    Download the Califf, Behrman and Kramer podcast as an mp3 file
  • Dr Brent Vose outlines AstraZeneca's oncology pipeline.
    Download the Dr. Brent Vose podcast as an mp3 file
view more

Webinars

  • Drug Delivery: enabling technology for discovery and development
    The integration of pharmacodynamic and pharmacokinetic parameters in non clinical pharmacology studies is a key aspect in drug discovery for efficacy and safety assessment, in the particular for the translation from the non clinical to the clinical field. Modeling the profile of plasma exposure achieved with the intended therapeutic route often requires the use of intravenous infusion. In addition, in most cases infusion parameters (infusion rate, volume, duration and sequences) need to be customized to achieve the appropriate pattern of plasma drug exposure. When pharmacodynamic parameters are recorded by telemetry, the use of implantable pumps rather than external pumps is necessary to preserve the improvement in physiological data recording offered by telemetry.
  • Enhancing productivity and accuracy in drug metabolism studies with the latest Orbitrap technology
    This webinar explores how productivity and accuracy in drug metabolism studies can be improved by employing the latest advancement in Orbitrap technology in pharmaceutical science and related industries
  • Part 2: How has HR-MS technology fundamentally changed the way we study drug biotransformation and disposition?
    AB SCIEX is proud to present the 2nd installment of a Global 4-Part Live Webinar Series exploring novel and dynamic workflows for Metabolite Identification & Drug Metabolism solutions as it pertains to the 4 main stages of the drug discovery and development paradigm, Lead Discovery, Late Stage Discovery, Early Development and Late Stage Development. Part 2 of this webinar series will focus on how HRMS technology has fundamentally changed the way metabolite biotransformations are investigated in Lead Discovery.
  • Industrialized Global Metabolite ID Solutions in the New Drug Discovery and Development Paradigm.
    AB SCIEX is proud to present the initial installment of a Global 4-Part Live Webinar Series exploring novel and dynamic workflows for Metabolite Identification & Drug Metabolism solutions as it pertains to the 4 main stages of the drug discovery and development paradigm, Lead Discovery, Late Stage Discovery, Early Development and Late Stage Development. Part 1 of this webinar series will focus on uniquely intelligent HRMS workflows for metabolite ID in Lead Discovery.
view more

Features

view more

Downloads

view more

25 Hottest Articles

view more
Copyright © 2012
Elsevier Ltd. All rights reserved.
Terms & Conditions | Privacy | Website Design Working with water